Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry
Por:
Pérez-Galindo, P, Gisbert, JP, Carrillo-Palau, M, Bertoletti, F, González-Vivó, M, Pajares, R, Merino, O, Ferrer, JA, Castaño, A, Chaparro, M, Calvo, M, Acosta, MBD, Lorente, RH, Algaba, A, Madero-Velázquez, L, Vela, M, de la Maza, S, Llaó, J, Vega, P, Utrilla, A, Almela, P, Domènech, E and Carpio, D
Publicada:
1 mar 2026
Resumen:
Background and Aims Evidence regarding the influence of vedolizumab (VDZ) on extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) is limited. Our aim was to analyze the effectiveness of VDZ in preexisting EIMs and the occurrence of de novo EIMs during VDZ therapy for IBD.Methods This observational, multicenter, retrospective cohort study included patients from the Spanish ENEIDA registry. All EIMs were assessed at baseline, and clinical response and worsening of IBD and EIMs were evaluated at 3 and 12 months after VDZ initiation, according to the physician's assessment.Results We retrospectively identified 551 patients with IBD treated with VDZ. At baseline, 133 patients (24.1%) had preexisting EIMs, with 77 having active EIMs. At 3 months, 29.9% of these patients showed clinical improvement, 16.9% experienced worsening, and 53.2% remained unchanged. Clinical response of IBD at 3 months was the only factor associated with EIM improvement (OR 3.72; 95% CI 1.08-12.83). Among 56 patients with inactive EIMs at baseline, 13.5% experienced worsening after 12 months. During follow-up, 25 patients (4.5%) developed 27 de novo EIMs. The presence of 2 preexisting EIMs was the only factor associated with de novo EIM onset (OR 16.2; 95% CI 4.3-60.9). Worsening of preexisting EIMs or de novo EIMs led to VDZ discontinuation in 15 patients (5.8% of all patients who discontinued VDZ and 2.7% of the entire cohort).Conclusions VDZ achieved clinical response of active EIMs in nearly one-third of patients after 3 months. Although infrequent, VDZ may exacerbate inactive EIMs and induce de novo EIMs during therapy, potentially leading to treatment discontinuation.
Filiaciones:
Pérez-Galindo, P:
Complejo Hosp Univ Pontevedra, Inst Invest Sanitaria Galicia Sur IISGS, Pontevedra, Spain
Gisbert, JP:
Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IIS IP, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Hosp Univ La Princesa, Madrid, Spain
Carrillo-Palau, M:
Hosp Univ Canarias, Tenerife, Spain
Bertoletti, F:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
González-Vivó, M:
Hosp del Mar, Barcelona, Spain
Pajares, R:
Hosp Univ Infanta Sofia, Madrid, Spain
Merino, O:
Hosp Univ Cruces, Baracaldo, Spain
Ferrer, JA:
Hosp Univ Fdn Alcorcon, Madrid, Spain
Castaño, A:
Hosp Univ Cent Asturias, Oviedo, Spain
Chaparro, M:
Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IIS IP, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Hosp Univ La Princesa, Madrid, Spain
Calvo, M:
Hosp Univ Puerta Hierro, Madrid, Spain
Acosta, MBD:
Hosp Clin Univ Santiago de Compostela, Santiago De Compostela, Spain
Lorente, RH:
Hosp Gen Univ Ciudad Real, Ciudad Real, Spain
Algaba, A:
Hosp Univ Fuenlabrada, Madrid, Spain
Madero-Velázquez, L:
Hosp Gen Univ Dr Balmis, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante, Spain
Vela, M:
Hosp Univ Nuestra Senora Candelaria, Santa Cruz de Tenerife, Spain
de la Maza, S:
Hosp Univ Basurto, Bilbao, Spain
Llaó, J:
Xarxa Assistencial Univ, Althaia, Manresa, Spain
Vega, P:
Complexo Hosp Univ Ourense, Orense, Spain
Utrilla, A:
Hosp Gen San Jorge, Huesca, Spain
Almela, P:
Hosp Gen Univ Castellon, Castellon de La Plana, Spain
:
Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Carpio, D:
Complejo Hosp Univ Pontevedra, Inst Invest Sanitaria Galicia Sur IISGS, Pontevedra, Spain
|